Active Trials

COVID-19: SARS Vaccination (SARS)

This is a multicenter, randomized, initially blinded (masked), phase 2 trial to assess SARS-CoV-2 vaccination reactions in two populations:

  • One population including individuals with a history of allergic reactions or Mast Cell Disorder (HA/MCD),and
  • One allergy-free population.

Approximately 2040 High-Allergy/Mast Cell Disorder (HA/MCD) and 1360 participants without allergies will be enrolled across participating sites in the United States (3400 total participants). Approximately two-thirds of participants enrolled in each of the 2 groups will be female. This is because the vast majority of cases of anaphylaxis to the COVID-19 vaccines have occurred in women.

Study Duration: Randomized and vaccinated participants will complete study participation in approximately 29 days if vaccinated with the Pfizer-BioNTech COVID-19 Vaccine, 36 days if vaccinated with the Moderna COVID-19 Vaccine, and 50 or 64 days if administered placebo before receiving two doses of either the Pfizer-BioNTech COVID-19 Vaccine or the Moderna COVID-19 Vaccine, respectively.

Total study duration: Approximately 17 weeks.

Active

(ACTIV-1 IM) Immune Modulators for Treating COVID-19

The research objectives are to evaluate each agent with respect to speed of recovery, mortality, illness severity, and hospital resource utilization

Principal Investigator
Marilyn Glassberg, MD

Location:
Other
Banner University Medical Center Phoenix, Arizona, 85006
Active

Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19) (CX4945)

To evaluate safety and explore clinical benefits of Silmitasertib 1000 mg BID dose in patients with severe illness caused be SARS-COV-2.

Principal Investigator
Marilyn Glassberg, MD

Location:
Banner University Medical Center - Tucson at 1625 N Campbell Ave, Tucson, AZ 85719
Banner University Medical Center-Phoenix at 1111 E McDowell Rd, Phoenix, AZ 85006
Active

Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults (PassItOn)

To assess the safety and efficacy of convalescent donor plasma to treat COVID-19 in hospitalized adults in a randomized, placebo-controlled setting.

To evaluate clinical efficacy of convalescent plasma compared to placebo, among adults with COVID-19 requiring hospitalization.

Principal Investigator
Marilyn Glassberg, MD

University of Arizona, Phoenix AZ
Active

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19

This study is randomized trial to assess the effectiveness and safety of using combination therapy drugs in treating COVID-19 patients. This study is active, but closing soon.

 

Objectives are to exclude futility of REGN10933+REGN10987 compared to placebo, as measured by death or mechanical ventilation; evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo Phase 2 (Cohort 1A); evaluate the clinical efficacy of REGN10933+REGN10987 compared to placebo, as measured by death or mechanical ventilation; evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo Phase 3 (Cohort 1 and Cohort 1A); and to evaluate the clinical efficacy of REGN10933+REGN10987 compared to placebo, as measured by death or mechanical ventilation

Principal Investigator
Marilyn Glassberg, MD

Location:
Other
Active

Anti-thrombotics for Adults Hospitalized With COVID-19 (ACTIV-4)

Principal Investigator
Dr. Afshin Sam and Joseph Bellal

Location:
Banner University Medical Center - Tucson at 1625 N Campbell Ave, Tucson, AZ 85719
Banner University Medical Center - South 2800 E Ajo Way, Tucson, AZ 85713
Active

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT

Principal Investigator
Drs. Sairam Parthasarathy and Franz Rischard

Location:
Alvernon CaTS Extension at University of Arizona, 655 N. Alvernon Way STE 108, Tucson, AZ 85716
Active

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19

To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo

Principal Investigator
Dr. Billie Bixby and Sairam Parthasarathy

Location:
Alvernon CaTS Extension at University of Arizona, 655 N. Alvernon Way STE 108, Tucson, AZ 85716
Active

PRESCO (Predictors of Severe COVID-19 Outcomes)

Performance (discrimination / calibration) of models [ Time Frame: From date of study enrollment until the date of first documented ARDS diagnosis or date of death from any cause, whichever comes first, assessed up to study end (estimated at 3 months). ] Performance (discrimination / calibration) of models that predict the risk of development of ARDS and/or mortality among COVID-19 patients who present to the hospital for evaluation and treatment.

Principal Investigator
Dr. Sairam Parthasarathy

Location:
CaTS Research Center at 1501 N Campbell Avenue, Tucson AZ 85724
Banner University Medical Center - Tucson at 1625 N Campbell Ave, Tucson, AZ 85719
Banner University Medical Center - South 2800 E Ajo Way, Tucson, AZ 85713
Alvernon CaTS Extension at University of Arizona, 655 N. Alvernon Way STE 108, Tucson, AZ 85716
Active

Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry (COVID-19)

Researchers are creating a real time COVID-19 registry of current ICU/hospital care patterns to allow evaluations of safety and observational effectiveness of COVID-19 practices and to determine the variations in practice across hospitals.

Principal Investigator
Jarrod Mosier, MD

Location:
Banner University Medical Center - Tucson at 1625 N Campbell Ave, Tucson, AZ 85719
Banner University Medical Center - South 2800 E Ajo Way, Tucson, AZ 85713
Active

Community-Engagement Research Alliance (CEAL) Against COVID-19 in Disproportionately Affected Communities

Principal Investigator
Dr. Sairam Parthasarathy

Location:
Banner University Medical Center - Tucson at 1625 N Campbell Ave, Tucson, AZ 85719
Banner University Medical Center - South 2800 E Ajo Way, Tucson, AZ 85713
Other
UArizona Health Sciences - Center for Sleep & Circadian Sciences
Active

BLUE - CORAL (Biology and Longitudinal Epidemiology of PETAL COVID-19 Observational Study)

Principal Investigator
Drs. Jarrod Mosier and Cameron Hypes

Location:
Banner University Medical Center - Tucson at 1625 N Campbell Ave, Tucson, AZ 85719
Banner University Medical Center - South 2800 E Ajo Way, Tucson, AZ 85713
Active

ACTIV-3

Principal Investigator
Dr. Jarrod Mosier

Location:
Banner University Medical Center - Tucson at 1625 N Campbell Ave, Tucson, AZ 85719
Banner University Medical Center - South 2800 E Ajo Way, Tucson, AZ 85713
Active